Close Menu

In the pending merger between Cambridge Antibody Technology and Oxford GlycoSciences, which the two companies announced on Jan. 23, a lot of questions remain as to what the combined company will look like, or what its new name will be. But there are indications that proteomics might play a smaller role in the new company than it has at OGS.

The merged firm is to be dominated by CAT’s management team and shareholders, with approximately $419 million in cash, two approved drugs, and 14 therapeutic products in either clinical or pre-clinical development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.